Endowave is a technology driven company focused on delivering the best in class flexible ablation catheter system.
Lung cancer is the most common cause of cancer deaths worldwide, with more than 1.8 million people diagnosed worldwide each year. It causes more deaths than breast and prostate cancers combined. It has a dismal 5 year survival rate of just 18%, compared to 99% for prostate and 89% for breast cancer. ENDOWAVE are developing a pioneering, minimally invasive treatment for lung cancer patients. Their patented catheter technology can be delivered through the patients airway directly to the target tumour site where it emits microwave energy to heat and destroy the diseased tissue. This novel approach will allow physicians to completely destroy a tumour in a single intervention using a minimally invasive approach, to improve patient outcomes and reduce treatment costs.